Systemic Kras ablation disrupts myeloid cell homeostasis in adult mice
Year: 2025
Type: article
Abstract: The KRAS oncogene has been associated with many types of cancer, including pancreatic, lung, and colorectal. For decades, its gene products were thought to be undruggable. However, during the last decade, a large battery of KRAS inhibitors selective against specific mutations (KRAS G12C and KRAS G12D ), panKRAS inhibitors active against all KRAS isoforms, or even panRAS inhibitors, capable of inhibiting the three members of the RAS family, have been developed. In mice, the Kras locus is essential for embryonic development and can sustain adult homeostasis in the absence of Hras and Nras expression. Thus, we considered of interest to interrogate the role of the Kras locus in an experimental system to generate potentially relevant information regarding the use of panKRAS or panRAS inhibitors in the clinic. Here, we report that systemic ablation of Kras expression in adult mice does not induce significant changes in overall survival, body weight, glucose levels, metabolic profile, or heart function. In contrast, flow cytometry and histopathological analyses of organs such as blood, bone marrow, and spleen showed a significant increase of the myeloid lineage leading to myelomonocytic metaplasia. In this context, replacement of the KRAS isoforms by HRAS is sufficient to maintain adult homeostasis, suggesting that the unique properties of the Kras locus are primarily due to its pattern of expression rather than to the activity of its gene products.
Authors: Elena Zamorano-Dominguez, Lucía Morales-Cacho, Rebeca Barrero, Silvia Jiménez-Parrado, Alma Dhawahir, Isabel Hernández-Porras, Lucía Simón-Carrasco, Sara Barrambana, Pian Sun, Ana Galván-del-Rey, Blanca Rosas-Perez, Vasiliki Liaki, Matthias Drosten, Mónica Musteanu, Federico Virga, Eugenio Santos, Francisca Mulero, Eduardo Caleiras, Carmen Guerra, Mariano Barbacid
Institutions: Instituto de Salud Carlos III, Spanish National Cancer Research Centre, Centro de Investigación Biomédica en Red de Cáncer, Roche (Switzerland), Consejo Superior de Investigaciones Científicas, Centro Andaluz de Biología Molecular y Medicina Regenerativa, Universidad de Sevilla, Universidad Pablo de Olavide, Universidad de Salamanca, Centro de Investigación del Cáncer, Universidad Complutense de Madrid, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Funders: F. Hoffmann-La Roche, Universidad de Sevilla, Ministerio de Ciencia, Innovación y Universidades, Mirati Therapeutics, AXA Research Fund, Universidad Complutense de Madrid, China Scholarship Council, Ministerio de Ciencia e Innovación, Centro Nacional de Investigaciones Cardiovasculares, Universidad de Salamanca, Centro de Investigación Biomédica en Red de Cáncer, CRIS Cancer Foundation, Consejo Superior de Investigaciones Científicas, Instituto de Salud Carlos III, Agencia Estatal de Investigación
OpenAlex ID: W4413301182
